David Williams to Schistosomicides
This is a "connection" page, showing publications David Williams has written about Schistosomicides.
Connection Strength
2.124
-
Characterization of Lead Compounds Targeting the Selenoprotein Thioredoxin Glutathione Reductase for Treatment of Schistosomiasis. ACS Infect Dis. 2020 03 13; 6(3):393-405.
Score: 0.672
-
The Schistosoma mansoni Cytochrome P450 (CYP3050A1) Is Essential for Worm Survival and Egg Development. PLoS Negl Trop Dis. 2015 Dec; 9(12):e0004279.
Score: 0.507
-
Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med. 2008 Apr; 14(4):407-12.
Score: 0.295
-
Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007 Jun; 4(6):e206.
Score: 0.280
-
Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo. Nat Commun. 2023 06 22; 14(1):3737.
Score: 0.213
-
Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med Chem. 2009 Oct 22; 52(20):6474-83.
Score: 0.082
-
A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Assay Drug Dev Technol. 2008 Aug; 6(4):551-5.
Score: 0.076